The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad151 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Danny Glickman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Penn State College of Medicine, Hershey, PA, USA. Hauptthemen laut MEDLINE: Hospitalization, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCCIH NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Cannabis use is common in inflammatory bowel disease (IBD). Recent studies demonstrated that use of cannabis may relieve symptoms; however, it is still unclear how safe cannabis and its derivatives are for IBD patients. We performed this study to evaluate the impact of cannabis use on several key clinical outcomes in IBD.
Methods
We performed a retrospective study using the TriNetX Diamond Network. Cannabis use and noncannabis use subcohorts were identified for 3 patient groups: (1) IBD, (2) Crohn’s disease (CD), and (3) ulcerative colitis (UC). Baseline differences between subcohorts for each group were controlled by propensity score matching. In each group, we compared relative incidence of emergency department (ED) visits, hospitalization, corticosteroid use, opioid use, IBD-related surgery, and death between cannabis users and noncannabis users.
Results
Inflammatory bowel disease cannabis users demonstrated an increased risk for corticosteroid use (risk ratios [R],1.095; 95% CI, 1.021-1.174; P = .011), ED visits (RR, 2.143; 95% CI, 2.034-2.257; P < .001), hospitalizations (RR, 1.925; 95% CI, 1.783-2.079; P < .001) and opioid use (RR, 1.35; 95% CI, 1.14-1.6); P < .001), but not an increased risk of IBD-related surgery or death. The CD and UC groups exhibited similar outcomes, except only CD demonstrated an increased risk for corticosteroid and opioid use.
Conclusions
Cannabis use in IBD patients is associated with several poor clinical outcomes, including increased risk of corticosteroid and opioid use, ED visits and hospitalization, though not IBD-related surgery or death. It is not clear what drives these risks or whether they are directly related to IBD-associated disease activity or other factors. Further prospective studies are warranted to more carefully investigate these relationships.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Penn State College of Medicine, Hershey, PA, USA.
- Penn State College of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Hershey, PA, USA.
- Penn State College of Medicine, Department of Pharmacology, Hershey, PA, USA.
ORCID-Profile: Matthew D Coates
Förderung
- NCCIH NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Complementary and Integrative Health
Zitieren
APA
Glickman, D., Dalessio, S., Raup-Konsavage, W. M., Vrana, K. E., & Coates, M. D. (2024). The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad151
Vancouver
Glickman D, Dalessio S, Raup-Konsavage WM, Vrana KE, Coates MD. The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad151
BibTeX
@article{Glickman2024,
author = {Glickman, Danny and Dalessio, Shannon and Raup-Konsavage, Wesley M and Vrana, Kent E and Coates, Matthew D},
title = {The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-based Longitudinal Cohort Study},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad151}
}
EUVIMED